Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing

被引:1
|
作者
Salama, Engie [1 ]
Lam, Stepfanie [1 ]
Gonsalves, Wilson, I [2 ]
Tzachanis, Dimitrios [3 ]
Momper, Jeremiah D. [1 ]
Saunders, Ila M. [1 ]
机构
[1] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, 9500 Gilman Dr,MC 0657, La Jolla, CA 92093 USA
[2] Mayo Clin, Div Hematol, Rochester, MN USA
[3] Univ Calif San Diego Hlth, Moores Canc Ctr, La Jolla, CA USA
关键词
multiple myeloma; pharmacokinetics; lenalidomide; renal impairment; CREATININE CLEARANCE; PHARMACOKINETICS; RECOMMENDATIONS;
D O I
10.1177/10600280221087218
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Lenalidomide is an immunomodulatory drug used to treat multiple myeloma that requires renal dosing adjustment based on Cockcroft-Gault (CG). Various equations to estimate kidney function exist and pose a potential issue with lenalidomide dosing. Objective The objective of this analysis was to evaluate the impact of estimating kidney function in newly diagnosed multiple myeloma patients with CG, Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and their potential impact on lenalidomide dosing. Methods Data from 1121 multiple myeloma patients at the time of diagnosis acquired from the Mayo Clinic were used to calculate creatinine clearance (CrCl) using Cockcroft-Gault with actual body weight (CG(ABW)), ideal body weight (CG(IBW)), or adjusted body weight (CG(AdjBW)); MDRD; and CKD-EPI for each subject. Discordances in dosing were then analyzed, and lenalidomide exposure was calculated for each subject to assess impact on pharmacokinetics of lenalidomide for patients who received discordant doses. Results Overall, approximately 16% of patients received a discordant dose when using MDRD or CKD-EPI instead of CG(ABW). The most common dose discordance was the decrease of a full dose of lenalidomide 25 mg when using CG(ABW) down to 10 mg and when using MDRD or CKD-EPI with 53.8% to 55.6% of all discordances in this category. When assessing different body weights, the most common discordance was a decrease from 25 to 10 mg when using CG(IBW) instead of CG(ABW); the same trend was observed when using CG(AdjBW) instead as well. Patients were also at risk of over- or underexposure based on area under the concentration versus time curve (AUC) for discordant dosing. Conclusion and Relevance A significant proportion of patients are at risk of under- or overdose of lenalidomide if CKD-EPI or MDRD are used instead of CG(ABW). Physicians should use CG(ABW) when estimating renal function to dose lenalidomide.
引用
收藏
页码:29 / 35
页数:7
相关论文
共 50 条
  • [1] An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma
    Popat, Rakesh
    Khan, Iftekhar
    Dickson, Jenny
    Cheesman, Simon
    Smith, Dean
    D'Sa, Shirley
    Rabin, Neil
    Yong, Kwee
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (01) : 148 - 151
  • [2] Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment
    Dimopoulos, Meletios A.
    Christoulas, Dimitrios
    Roussou, Maria
    Kastritis, Efstathios
    Migkou, Magdalini
    Gavriatopoulou, Maria
    Gkotzamanidou, Maria
    Iakovaki, Marina
    Matsouka, Charis
    Mparmparoussi, Despina
    Psimenou, Erasmia
    Grapsa, Irini
    Efstathiou, Eleni
    Terpos, Evangelos
    BLOOD, 2009, 114 (22) : 1489 - 1489
  • [3] Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment
    Dimopoulos, Meletios A.
    Christoulas, Dimitrios
    Roussou, Maria
    Kastritis, Efstathios
    Migkou, Magdalini
    Gavriatopoulou, Maria
    Matsouka, Charis
    Mparmparoussi, Despoina
    Psimenou, Erasmia
    Grapsa, Irini
    Efstathiou, Eleni
    Terpos, Evangelos
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (01) : 1 - 5
  • [4] Estimation of Kidney Function in Oncology Implications for Anticancer Drug Selection and Dosing
    Casal, Morgan A.
    Nolin, Thomas A.
    Beumer, Jan H.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 14 (04): : 587 - 595
  • [5] GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study
    Schmidts, Andrea
    Gruenewald, Julian
    Kleber, Martina
    Terpos, Evangelos
    Ihorst, Gabriele
    Reinhardt, Heike
    Walz, Gerd
    Waesch, Ralph
    Engelhardt, Monika
    Zschiedrich, Stefan
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2019, 23 (02) : 199 - 206
  • [6] GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study
    Andrea Schmidts
    Julian Grünewald
    Martina Kleber
    Evangelos Terpos
    Gabriele Ihorst
    Heike Reinhardt
    Gerd Walz
    Ralph Wäsch
    Monika Engelhardt
    Stefan Zschiedrich
    Clinical and Experimental Nephrology, 2019, 23 : 199 - 206
  • [7] Pharmacoeconomic Implications of Lenalidomide Maintenance Therapy in Multiple Myeloma
    Kim, Miriam Y.
    Sposto, Richard
    Swaika, Abhisek
    Asano, Hitomi
    Alamgir, Ahsan
    Chanan-Khan, Asher
    Ailawadhi, Sikander
    ONCOLOGY, 2014, 87 (04) : 224 - 231
  • [8] Hyperuricemia and Kidney Function in Patients Diagnosed With Multiple Myeloma
    Petreski, Tadej
    Pulko, Nejc
    Sapek, Katja
    Puljek, Sanja
    Piko, Nejc
    Bevc, Sebastjan
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 636 - 636
  • [9] Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma
    Manh-Cuong Vo
    Truc Anh-NguyenThi
    Lee, Hyun-Ju
    Thanh-Nhan Nguyen-Pham
    Lakshmi, Thangaraj Jaya
    Jung, Sung-Hoon
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    EXPERIMENTAL HEMATOLOGY, 2017, 46 : 48 - 55
  • [10] Pharmacokinetic and bioequivalence of lenalidomide in multiple myeloma patients
    Shen, Qi
    Gao, Tiantao
    Xiang, Jin
    Feng, Ping
    Liu, Xinghong
    Zheng, Li
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2023, 61 (04) : 181 - 188